Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1

This study has been completed.
New York State Psychiatric Institute
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: September 20, 1999
Last updated: June 23, 2005
Last verified: April 1996
The purpose of this study is to evaluate the safety and efficacy of flupenthixol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.

Condition Intervention Phase
Cocaine-Related Disorders
Drug: Flupenthixol
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Flupenthixol Treatment in Schizophrenic Cocaine Abusers

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Side effects
  • Craving
  • Drug use
  • Psychiatric symptoms

Estimated Enrollment: 0
Study Start Date: August 1994
Estimated Study Completion Date: December 2001

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000266

United States, New York
New York State Psychiatric Institute
New York, New York, United States, 10032
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
New York State Psychiatric Institute
Principal Investigator: Herbert Kleber, M.D. New York State Psychiatric Institute
  More Information Identifier: NCT00000266     History of Changes
Other Study ID Numbers: NIDA-09236-1  P50-09236-1 
Study First Received: September 20, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Flupenthixol decanoate
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Antipsychotic Agents
Tranquilizing Agents
Psychotropic Drugs
Dopamine Antagonists processed this record on October 21, 2016